Dengue Virus Immunopathogenesis: Lessons Applicable to the Emergence of Zika Virus

Journal of Molecular Biology

Volumn 428, Issue 17, 2016, Pages 3429-3448

  Olagnier, David ^a   Amatore, Donatella ^b   Castiello, Luciano ^c   Ferrari, Matteo ^c   Palermo, Enrico ^c   Diamond, Michael S ^d   Palamara, Anna Teresa ^b,c   Hiscott, John ^c  

^a MCGILL UNIVERSITY   (Canada)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Pasteur Institute   (Italy)

^d WASHINGTON UNIVERSITY   (United States)

Author keywords

dengue; innate immunity; oxidative stress; pathogenesis; Zika

Indexed keywords

ANTIVIRUS AGENT; VIRUS VACCINE; VIRUS VECTOR;

ADAPTIVE IMMUNITY; AEDES AEGYPTI; ANTIBODY DEPENDENT ENHANCEMENT; ARBOVIRUS; CHIKUNGUNYA VIRUS; CLINICAL FEATURE; DENGUE; DENGUE HEMORRHAGIC FEVER; DENGUE VIRUS; DISEASE SEVERITY; HUMAN; IMMUNOPATHOGENESIS; INNATE IMMUNITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SHOCK; SIGNAL TRANSDUCTION; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; VIRUS PATHOGENESIS; YELLOW FEVER VIRUS; ZIKA VIRUS; AEDES; ANIMAL; HOST PATHOGEN INTERACTION; IMMUNOLOGY; PATHOGENICITY; VIROLOGY;

AEDES; ANIMALS; DENGUE VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; OXIDATIVE STRESS; ZIKA VIRUS;

EID: 84965053744     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2016.04.024     Document Type: Review

References (182)

1. [1] Rothman, A.L., Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat. Rev. Immunol. 11 (2011), 532–543, 10.1038/nri3014.
2. [2] Halstead, S.B., Dengue virus–mosquito interactions. Annu. Rev. Entomol. 53 (2008), 273–291, 10.1146/annurev.ento.53.103106.093326.
3. [3] Wilder-Smith, A., Ooi, E.-E., Vasudevan, S.G., Gubler, D.J., Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr. Infect. Dis. Rep. 12 (2010), 157–164, 10.1007/s11908-010-0102-7.
4. [4] Dick, G.W.A., Kitchen, S.F., Haddow, A.J., Zika virus. I. Isolations and serological specificity. Trans. R. Soc. Trop. Med. Hyg. 46 (1952), 509–520.
5. [5] Berthet, N., Nakoune, E., Kamgang, B., Selekon, B., Descorps-Declere, S., Gessain, A., et al., Molecular characterization of three Zika flaviviruses obtained from sylvatic mosquitoes in the Central African Republic. Vector Borne Zoonotic Dis. 14 (2014), 862–865, 10.1089/vbz.2014.1607.
6. [6] Zammarchi, L., Stella, G., Mantella, A., Bartolozzi, D., Tappe, D., Gunther, S., et al., Zika virus infections imported to Italy: clinical, immunological and virological findings, and public health implications. J. Clin. Virol. 63 (2015), 32–35, 10.1016/j.jcv.2014.12.005.
7. [7] Faye, O., Freire, C.C.M., Iamarino, A., Faye, O., de Oliveira, J.V.C., Diallo, M., et al., Molecular evolution of Zika virus during its emergence in the 20(th) century. PLoS Negl. Trop. Dis., 8, 2014, e2636, 10.1371/journal.pntd.0002636.
8. [8] Dupont-Rouzeyrol, M., Biron, A., O'Connor, O., Huguon, E., Descloux, E., Infectious Zika viral particles in breastmilk. Lancet, 387, 2016, 1051, 10.1016/S0140-6736(16)00624-3.
9. [9] Shurtleff, A.C., Beasley, D.W., Chen, J.J., Ni, H., Suderman, M.T., Wang, H., et al., Genetic variation in the 3′ non-coding region of dengue viruses. Virology 281 (2001), 75–87, 10.1006/viro.2000.0748.
10. [10] Silva, R.L.A., de Silva, A.M., Harris, E., MacDonald, G.H., Genetic analysis of dengue 3 virus subtype III 5′ and 3′ non-coding regions. Virus Res. 135 (2008), 320–325, 10.1016/j.virusres.2008.03.007.
11. [11] Vasilakis, N., Weaver, S.C., The history and evolution of human dengue emergence. Adv. Virus Res. 72 (2008), 1–76, 10.1016/S0065-3527(08)00401-6.
12. [12] Zhou, Y., Mammen, M.P., Klungthong, C., Chinnawirotpisan, P., Vaughn, D.W., Nimmannitya, S., et al., Comparative analysis reveals no consistent association between the secondary structure of the 3′-untranslated region of dengue viruses and disease syndrome. J. Gen. Virol. 87 (2006), 2595–2603, 10.1099/vir.0.81994-0.
13. [13] Green, A.M., Beatty, P.R., Hadjilaou, A., Harris, E., Innate immunity to dengue virus infection and subversion of antiviral responses. J. Mol. Biol. 426 (2014), 1148–1160, 10.1016/j.jmb.2013.11.023.
14. [14] Dejnirattisai, W., Jumnainsong, A., Onsirisakul, N., Fitton, P., Vasanawathana, S., Limpitikul, W., et al., Cross-reacting antibodies enhance dengue virus infection in humans. Science 328 (2010), 745–748, 10.1126/science.1185181.
15. [15] Beltramello, M., Williams, K.L., Simmons, C.P., Macagno, A., Simonelli, L., Quyen, N.T.H., et al., The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8 (2010), 271–283, 10.1016/j.chom.2010.08.007.
16. [16] de Alwis, R., Beltramello, M., Messer, W.B., Sukupolvi-Petty, S., Wahala, W.M.P.B., Kraus, A., et al., In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl. Trop. Dis., 5, 2011, e1188, 10.1371/journal.pntd.0001188.
17. [17] Tappe, D., Perez-Giron, J.V., Zammarchi, L., Rissland, J., Ferreira, D.F., Jaenisch, T., et al., Cytokine kinetics of Zika virus-infected patients from acute to reconvalescent phase. Med. Microbiol. Immunol., 2015, 10.1007/s00430–015–0445-7.
18. [18] Kelser, E.A., Meet dengue's cousin, Zika. Microbes Infect., 2015, 10.1016/j.micinf.2015.12.003.
19. [19] Mlakar, J., Korva, M., Tul, N., Popovic, M., Poljsak-Prijatelj, M., Mraz, J., et al., Zika virus associated with microcephaly. N. Engl. J. Med., 2016, 10.1056/NEJMoa1600651.
20. [20] Sirohi, D., Chen, Z., Sun, L., Klose, T., Pierson, T.C., Rossmann, M.G., et al., The 3.8 a resolution cryo-EM structure of Zika virus. Science(80-.), 2016, 10.1126/science.aaf5316.
21. [21] Huy, N.T., Van Giang, T., Thuy, D.H.D., Kikuchi, M., Hien, T.T., Zamora, J., et al., Factors associated with dengue shock syndrome: a systematic review and meta-analysis. PLoS Negl. Trop. Dis., 7, 2013, e2412, 10.1371/journal.pntd.0002412.
22. [22] Halstead, S.B., Dengue. Lancet (Lond. Engl.) 370 (2007), 1644–1652, 10.1016/S0140–6736(07)61687–0.
23. [23] Musso, D., Cao-Lormeau, V.M., Gubler, D.J., Zika virus: following the path of dengue and chikungunya?. Lancet 386 (2015), 243–244, 10.1016/S0140-6736(15)61273-9.
24. [24] Cao-Lormeau, V.-M., Blake, A., Mons, S., Lastère, S., Roche, C., Vanhomwegen, J., et al., Guillain–Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case–control study. Lancet, 2016, 10.1016/S0140-6736(16)00562-6.
25. [25] Malkki, H., CNS infections: Zika virus infection could trigger Guillain–Barré syndrome. Nat. Rev. Neurol., 12, 2016, 187, 10.1038/nrneurol.2016.30.
26. [26] Ventura, C.V., Maia, M., Bravo-Filho, V., Góis, A.L., Belfort, R., Zika virus in Brazil and macular atrophy in a child with microcephaly. Lancet, 387, 2016, 228, 10.1016/S0140–6736(16)00006–4.
27. [27] Oliveira Melo, A.S., Malinger, G., Ximenes, R., Szejnfeld, P.O., Alves Sampaio, S., Bispo de Filippis, A.M., Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg?. Ultrasound Obstet. Gynecol. 47 (2016), 6–7, 10.1002/uog.15831.
28. [28] Driggers, R.W., Ho, C.-Y., Korhonen, E.M., Kuivanen, S., Jääskeläinen, A.J., Smura, T., et al., Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. N. Engl. J. Med., 2016, 10.1056/NEJMoa1601824.
29. [29] Cauchemez, S., Besnard, M., Bompard, P., Dub, T., Guillemette-Artur, P., Eyrolle-Guignot, D., et al., Association between Zika virus and microcephaly in French Polynesia, 2013–15: a retrospective study. Lancet, 2016, 10.1016/S0140-6736(16)00651-6.
30. [30] Tang, H., Hammack, C., Ogden, S.C., Wen, Z., Qian, X., Li, Y., et al., Zika virus infects human cortical neural progenitors and attenuates their growth. Cell Stem Cell, 2016, 10.1016/j.stem.2016.02.016.
31. [31] Bhatt, S., Gething, P.W., Brady, O.J., Messina, J.P., Farlow, A.W., Moyes, C.L., et al., The global distribution and burden of dengue. Nature 496 (2013), 504–507, 10.1038/nature12060.
32. [32] Guzman, M.G., Halstead, S.B., Artsob, H., Buchy, P., Farrar, J., Gubler, D.J., et al., Dengue: a continuing global threat. Nat. Rev. Microbiol. 8 (2010), S7–S16, 10.1038/nrmicro2460.
33. [33] San Martín, J.L., Brathwaite, O., Zambrano, B., Solórzano, J.O., Bouckenooghe, A., Dayan, G.H., et al., The epidemiology of dengue in the americas over the last three decades: a worrisome reality. Am.J.Trop. Med. Hyg. 82 (2010), 128–135, 10.4269/ajtmh.2010.09-0346.
34. [34] Fredericks, A.C., Fernandez-Sesma, A., The burden of dengue and chikungunya worldwide: implications for the Southern United States and California. Ann. Glob. Health 80 (2014), 466–475, 10.1016/j.aogh.2015.02.006.
35. [35] Teets, F.D., Ramgopal, M.N., Sweeney, K.D., Graham, A.S., Michael, S.F., Isern, S., Origin of the dengue virus outbreak in Martin County, Florida, USA. Virol. Rep. 1-2 (2013), 2–8, 10.1016/j.virep.2014.05.001.
36. [36] Martina, B.E.E., Koraka, P., Osterhaus, A.D.M.E., Dengue virus pathogenesis: an integrated view. Clin. Microbiol. Rev. 22 (2009), 564–581, 10.1128/CMR.00035-09.
37. [37] Cardier, J.E., Balogh, V., Perez-Silva, C., Romano, E., Rivas, B., Bosch, N., et al., Relationship of thrombopoietin and interleukin-11 levels to thrombocytopenia associated with dengue disease. Cytokine 34 (2006), 155–160, 10.1016/j.cyto.2006.04.002.
38. [38] Butthep, P., Chunhakan, S., Tangnararatchakit, K., Yoksan, S., Pattanapanyasat, K., Chuansumrit, A., Elevated soluble thrombomodulin in the febrile stage related to patients at risk for dengue shock syndrome. Pediatr. Infect. Dis. J. 25 (2006), 894–897, 10.1097/01.inf.0000237918.85330.b9.
39. [39] Green, S., Vaughn, D.W., Kalayanarooj, S., Nimmannitya, S., Suntayakorn, S., Nisalak, A., et al., Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. J. Med. Virol. 59 (1999), 329–334.
40. [40] Green, S., Vaughn, D.W., Kalayanarooj, S., Nimmannitya, S., Suntayakorn, S., Nisalak, A., et al., Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J. Infect. Dis. 179 (1999), 755–762, 10.1086/314680.
41. [41] Kalayanarooj, S., Vaughn, D.W., Nimmannitya, S., Green, S., Suntayakorn, S., Kunentrasai, N., et al., Early clinical and laboratory indicators of acute dengue illness. J. Infect. Dis. 176 (1997), 313–321.
42. [42] Nascimento, E.J.M., Silva, A.M., Cordeiro, M.T., Brito, C.A., Gil, L.H.V.G., Braga-Neto, U., et al., Alternative complement pathway deregulation is correlated with dengue severity. PLoS One, 4, 2009, e6782, 10.1371/journal.pone.0006782.
43. [43] Messer, W.B., Gubler, D.J., Harris, E., Sivananthan, K., de Silva, A.M., Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg. Infect. Dis. 9 (2003), 800–809.
44. [44] Balsitis, S.J., Williams, K.L., Lachica, R., Flores, D., Kyle, J.L., Mehlhop, E., et al., Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog., 6, 2010, e1000790, 10.1371/journal.ppat.1000790.
45. [45] Endy, T.P., Nisalak, A., Chunsuttitwat, S., Vaughn, D.W., Green, S., Ennis, F.A., et al., Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 189 (2004), 990–1000, 10.1086/382280.
46. [46] Halstead, S.B., O'Rourke, E.J., Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med. 146 (1977), 201–217.
47. [47] Schieffelin, J.S., Costin, J.M., Nicholson, C.O., Orgeron, N.M., Fontaine, K.A., Isern, S., et al., Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol. J., 7, 2010, 28, 10.1186/1743-422X-7-28.
48. [48] Loke, H., Bethell, D., Phuong, C.X.T., Day, N., White, N., Farrar, J., et al., Susceptibility to dengue hemorrhagic fever in Vietnam: evidence of an association with variation in the vitamin d receptor and Fc gamma receptor IIa genes. Am.J.Trop. Med. Hyg. 67 (2002), 102–106.
49. [49] Sakuntabhai, A., Turbpaiboon, C., Casadémont, I., Chuansumrit, A., Lowhnoo, T., Kajaste-Rudnitski, A., et al., A variant in the CD209 promoter is associated with severity of dengue disease. Nat. Genet. 37 (2005), 507–513, 10.1038/ng1550.
50. [50] Fernández-Mestre, M.T., Gendzekhadze, K., Rivas-Vetencourt, P., Layrisse, Z., TNF-alpha-308 A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. Tissue Antigens 64 (2004), 469–472, 10.1111/j.1399-0039.2004.00304.x.
51. [51] Halstead, S.B., Mahalingam, S., Marovich, M.A., Ubol, S., Mosser, D.M., Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect. Dis. 10 (2010), 712–722, 10.1016/S1473-3099(10)70166-3.
52. [52] Diamond, M.S., Pierson, T.C., Molecular insight into dengue virus pathogenesis and its implications for disease control. Cell 162 (2015), 488–492, 10.1016/j.cell.2015.07.005.
53. [53] Rodenhuis-Zybert, I.A., Wilschut, J., Smit, J.M., Dengue virus life cycle: viral and host factors modulating infectivity. Cell. Mol. Life Sci. 67 (2010), 2773–2786, 10.1007/s00018-010-0357-z.
54. [54] Rodenhuis-Zybert, I.A., Moesker, B., da Silva Voorham, J.M., van der Ende-Metselaar, H., Diamond, M.S., Wilschut, J., et al., A fusion-loop antibody enhances the infectious properties of immature flavivirus particles. J. Virol. 85 (2011), 11800–11808, 10.1128/JVI.05237-11.
55. [55] Littaua, R., Kurane, I., Ennis, F.A., Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J. Immunol. 144 (1990), 3183–3186.
56. [56] Rodrigo, W.W.S.I., Block, O.K.T., Lane, C., Sukupolvi-Petty, S., Goncalvez, A.P., Johnson, S., et al., Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype. Virology 394 (2009), 175–182, 10.1016/j.virol.2009.09.024.
57. [57] Rodrigo, W.W.S.I., Jin, X., Blackley, S.D., Rose, R.C., Schlesinger, J.J., Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J. Virol. 80 (2006), 10128–10138, 10.1128/JVI.00792-06.
58. [58] Boonnak, K., Slike, B.M., Donofrio, G.C., Marovich, M.A., Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection. J. Immunol. 190 (2013), 5659–5665, 10.4049/jimmunol.1203052.
59. [59] Sun, P., Kochel, T.J., The battle between infection and host immune responses of dengue virus and its implication in dengue disease pathogenesis. ScientificWorldJournal, 2013, 2013, 843469, 10.1155/2013/843469.
60. [60] Callaway, J.B., Smith, S.A., McKinnon, K.P., de Silva, A.M., Crowe, J.E., Ting, J.P.-Y., Spleen tyrosine kinase (Syk) mediates IL-1β induction by primary human monocytes during antibody-enhanced dengue virus infection. J. Biol. Chem. 290 (2015), 17306–17320, 10.1074/jbc.M115.664136.
61. [61] Bozza, F.A., Cruz, O.G., Zagne, S.M.O., Azeredo, E.L., Nogueira, R.M.R., Assis, E.F., et al., Multiplex cytokine profile from dengue patients: MIP-1beta and IFN-gamma as predictive factors for severity. BMC Infect. Dis., 8, 2008, 86, 10.1186/1471-2334-8-86.
62. [62] McCord, J.M., Fridovich, I., The reduction of cytochrome c by milk xanthine oxidase. J. Biol. Chem. 243 (1968), 5753–5760.
63. [63] Pacher, P., Nivorozhkin, A., Szabó, C., Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev. 58 (2006), 87–114, 10.1124/pr.58.1.6.
64. [64] Zangar, R.C., Davydov, D.R., Verma, S., Mechanisms that regulate production of reactive oxygen species by cytochrome P450. Toxicol. Appl. Pharmacol. 199 (2004), 316–331, 10.1016/j.taap.2004.01.018.
65. [65] Vásquez-Vivar, J., Kalyanaraman, B., Martásek, P., Hogg, N., Masters, B.S., Karoui, H., et al., Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 9220–9225.
66. [66] Alp, N.J., Channon, K.M., Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler. Thromb. Vasc. Biol. 24 (2004), 413–420, 10.1161/01.ATV.0000110785.96039.f6.
67. [67] Simmons, D.L., Botting, R.M., Hla, T., Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 56 (2004), 387–437, 10.1124/pr.56.3.3.
68. [68] Kuhn, H., Banthiya, S., van Leyen, K., Mammalian lipoxygenases and their biological relevance. Biochim. Biophys. Acta 1851 (2015), 308–330, 10.1016/j.bbalip.2014.10.002.
69. [69] Nickel, A., Kohlhaas, M., Maack, C., Mitochondrial reactive oxygen species production and elimination. J. Mol. Cell. Cardiol. 73 (2014), 26–33, 10.1016/j.yjmcc.2014.03.011.
70. [70] Vignais, P.V., The superoxide-generating NADPH oxidase: structural aspects and activation mechanism. Cell. Mol. Life Sci. 59 (2002), 1428–1459.
71. [71] Bedard, K., Lardy, B., Krause, K.-H., NOX family NADPH oxidases: not just in mammals. Biochimie 89 (2007), 1107–1112, 10.1016/j.biochi.2007.01.012.
72. [72] Ma, Q., He, X., Molecular basis of electrophilic and oxidative defense: promises and perils of Nrf2. Pharmacol. Rev. 64 (2012), 1055–1081, 10.1124/pr.110.004333.
73. [73] Ma, Q., Role of Nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 53 (2013), 401–426, 10.1146/annurev-pharmtox-011112-140320.
74. [74] Bryan, H.K., Olayanju, A., Goldring, C.E., Park, B.K., The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem. Pharmacol. 85 (2013), 705–717, 10.1016/j.bcp.2012.11.016.
75. [75] Gutteridge, J.M., Halliwell, B., Iron toxicity and oxygen radicals. Baillieres Clin. Haematol. 2 (1989), 195–256.
76. [76] Filomeni, G., Rotilio, G., Ciriolo, M.R., Disulfide relays and phosphorylative cascades: partners in redox-mediated signaling pathways. Cell Death Differ. 12 (2005), 1555–1563, 10.1038/sj.cdd.4401754.
77. [77] Dröge, W., Aging-related changes in the thiol/disulfide redox state: implications for the use of thiol antioxidants. Exp. Gerontol. 37 (2002), 1333–1345.
78. [78] Schafer, F.Q., Buettner, G.R., Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 30 (2001), 1191–1212.
79. [79] Dickinson, D.A., Forman, H.J., Cellular glutathione and thiols metabolism. Biochem. Pharmacol. 64 (2002), 1019–1026.
80. [80] Ghezzi, P., Regulation of protein function by glutathionylation. Free Radic. Res. 39 (2005), 573–580, 10.1080/10715760500072172.
81. [81] Ghezzi, P., Protein glutathionylation in health and disease. Biochim. Biophys. Acta 1830 (2013), 3165–3172, 10.1016/j.bbagen.2013.02.009.
82. [82] Garaci, E., Palamara, A.T., Di Francesco, P., Favalli, C., Ciriolo, M.R., Rotilio, G., Glutathione inhibits replication and expression of viral proteins in cultured cells infected with Sendai virus. Biochem. Biophys. Res. Commun. 188 (1992), 1090–1096.
83. [83] Garaci, E., Palamara, A.T., Ciriolo, M.R., D'Agostini, C., Abdel-Latif, M.S., Aquaro, S., et al., Intracellular GSH content and HIV replication in human macrophages. J. Leukoc. Biol. 62 (1997), 54–59.
84. [84] Palamara, A.T., Perno, C.F., Ciriolo, M.R., Dini, L., Balestra, E., D'Agostini, C., et al., Evidence for antiviral activity of glutathione: in vitro inhibition of herpes simplex virus type 1 replication. Antivir. Res. 27 (1995), 237–253.
85. [85] Palamara, A.T., Garaci, E., Rotilio, G., Ciriolo, M.R., Casabianca, A., Fraternale, A., et al., Inhibition of murine AIDS by reduced glutathione. AIDS Res. Hum. Retrovir. 12 (1996), 1373–1381.
86. [86] Ciriolo, M.R., Palamara, A.T., Incerpi, S., Lafavia, E., Buè, M.C., De Vito, P., et al., Loss of GSH, oxidative stress, and decrease of intracellular pH as sequential steps in viral infection. J. Biol. Chem. 272 (1997), 2700–2708.
87. [87] Amatore, D., Sgarbanti, R., Aquilano, K., Baldelli, S., Limongi, D., Civitelli, L., et al., Influenza virus replication in lung epithelial cells depends on redox-sensitive pathways activated by NOX4-derived ROS. Cell. Microbiol. 17 (2015), 131–145, 10.1111/cmi.12343.
88. [88] Akaike, T., Noguchi, Y., Ijiri, S., Setoguchi, K., Suga, M., Zheng, Y.M., et al., Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 2448–2453.
89. [89] Imai, Y., Kuba, K., Neely, G.G., Yaghubian-Malhami, R., Perkmann, T., van Loo, G., et al., Identification of oxidative stress and toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133 (2008), 235–249, 10.1016/j.cell.2008.02.043.
90. [90] Vlahos, R., Stambas, J., Bozinovski, S., Broughton, B.R.S., Drummond, G.R., Selemidis, S., Inhibition of Nox2 oxidase activity ameliorates influenza A virus-induced lung inflammation. PLoS Pathog., 7, 2011, e1001271, 10.1371/journal.ppat.1001271.
91. [91] Vlahos, R., Stambas, J., Selemidis, S., Suppressing production of reactive oxygen species (ROS) for influenza A virus therapy. Trends Pharmacol. Sci. 33 (2012), 3–8, 10.1016/j.tips.2011.09.001.
92. [92] Cai, J., Chen, Y., Seth, S., Furukawa, S., Compans, R.W., Jones, D.P., Inhibition of influenza infection by glutathione. Free Radic. Biol. Med. 34 (2003), 928–936.
93. [93] Nencioni, L., Iuvara, A., Aquilano, K., Ciriolo, M.R., Cozzolino, F., Rotilio, G., et al., Influenza a virus replication is dependent on an antioxidant pathway that involves GSH and Bcl-2. FASEB J. 17 (2003), 758–760, 10.1096/fj.02-0508fje.
94. [94] Sgarbanti, R., Nencioni, L., Amatore, D., Coluccio, P., Fraternale, A., Sale, P., et al., Redox regulation of the influenza hemagglutinin maturation process: a new cell-mediated strategy for anti-influenza therapy. Antioxid. Redox Signal. 15 (2011), 593–606, 10.1089/ars.2010.3512.
95. [95] Ivanov, A.V., Smirnova, O.A., Ivanova, O.N., Masalova, O.V., Kochetkov, S.N., Isaguliants, M.G., Hepatitis C virus proteins activate NRF2/ARE pathway by distinct ROS-dependent and independent mechanisms in HUH7 cells. PLoS One, 6, 2011, e24957, 10.1371/journal.pone.0024957.
96. [96] Ke, P.-Y., Chen, S.S.-L., Hepatitis C virus and cellular stress response: implications to molecular pathogenesis of liver diseases. Viruses 4 (2012), 2251–2290, 10.3390/v4102251.
97. [97] Paracha, U.Z., Fatima, K., Alqahtani, M., Chaudhary, A., Abuzenadah, A., Damanhouri, G., et al., Oxidative stress and hepatitis C virus. Virol. J., 10, 2013, 251, 10.1186/1743-422X-10-251.
98. [98] Yen, Y.-T., Chen, H.-C., Chen, H.-C., Lin, Y.-D., Shieh, C.-C., Wu-Hsieh, B.A., Enhancement by tumor necrosis factor alpha of dengue virus-induced endothelial cell production of reactive nitrogen and oxygen species is key to hemorrhage development. J. Virol. 82 (2008), 12312–12324, 10.1128/JVI.00968-08.
99. [99] Wang, J., Chen, Y., Gao, N., Wang, Y., Tian, Y., Wu, J., et al., Inhibitory effect of glutathione on oxidative liver injury induced by dengue virus serotype 2 infections in mice. PLoS One, 8, 2013, e55407, 10.1371/journal.pone.0055407.
100. [100] Marianneau, P., Steffan, A.M., Royer, C., Drouet, M.T., Jaeck, D., Kirn, A., et al., Infection of primary cultures of human Kupffer cells by dengue virus: no viral progeny synthesis, but cytokine production is evident. J. Virol. 73 (1999), 5201–5206.
101. [101] Jan, J.T., Chen, B.H., Ma, S.H., Liu, C.I., Tsai, H.P., Wu, H.C., et al., Potential dengue virus-triggered apoptotic pathway in human neuroblastoma cells: arachidonic acid, superoxide anion, and NF-kappaB are sequentially involved. J. Virol. 74 (2000), 8680–8691.
102. [102] Neves-Souza, P.C.F., Azeredo, E.L., Zagne, S.M.O., Valls-de-Souza, R., Reis, S.R.N.I., Cerqueira, D.I.S., et al., Inducible nitric oxide synthase (iNOS) expression in monocytes during acute dengue fever in patients and during in vitro infection. BMC Infect. Dis., 5, 2005, 64, 10.1186/1471-2334-5-64.
103. [103] Tian, Y., Jiang, W., Gao, N., Zhang, J., Chen, W., Fan, D., et al., Inhibitory effects of glutathione on dengue virus production. Biochem. Biophys. Res. Commun. 397 (2010), 420–424, 10.1016/j.bbrc.2010.05.108.
104. [104] Lin, Y.L., Liu, C.C., Chuang, J.I., Lei, H.Y., Yeh, T.M., Lin, Y.S., et al., Involvement of oxidative stress, NF-IL-6, and RANTES expression in dengue-2-virus-infected human liver cells. Virology 276 (2000), 114–126, 10.1006/viro.2000.0524.
105. [105] Al-Alimi, A.A., Ali, S.A., Al-Hassan, F.M., Idris, F.M., Teow, S.-Y., Mohd Yusoff, N., Dengue virus type 2 (DENV2)-induced oxidative responses in monocytes from glucose-6-phosphate dehydrogenase (G6PD)-deficient and G6PD normal subjects. PLoS Negl. Trop. Dis., 8, 2014, e2711, 10.1371/journal.pntd.0002711.
106. [106] Chareonsirisuthigul, T., Kalayanarooj, S., Ubol, S., Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J. Gen. Virol. 88 (2007), 365–375, 10.1099/vir.0.82537-0.
107. [107] Olagnier, D., Peri, S., Steel, C., van Montfoort, N., Chiang, C., Beljanski, V., et al., Cellular oxidative stress response controls the antiviral and apoptotic programs in dengue virus-infected dendritic cells. PLoS Pathog., 10, 2014, e1004566, 10.1371/journal.ppat.1004566.
108. [108] Castro, R., Pinzón, H.S., Alvis-Guzman, N., A systematic review of observational studies on oxidative/nitrosative stress involvement in dengue pathogenesis. Colomb. Méd. (Cali Colomb.) 46 (2015), 135–143.
109. [109] Gil, L., Martínez, G., Tápanes, R., Castro, O., González, D., Bernardo, L., et al., Oxidative stress in adult dengue patients. Am.J.Trop. Med. Hyg. 71 (2004), 652–657.
110. [110] Seet, R.C.S., Lee, C.-Y.J., Lim, E.C.H., Quek, A.M.L., Yeo, L.L.L., Huang, S.-H., et al., Oxidative damage in dengue fever. Free Radic. Biol. Med. 47 (2009), 375–380, 10.1016/j.freeradbiomed.2009.04.035.
111. [111] Soundravally, R., Sankar, P., Bobby, Z., Hoti, S.L., Oxidative stress in severe dengue viral infection: association of thrombocytopenia with lipid peroxidation. Platelets 19 (2008), 447–454, 10.1080/09537100802155284.
112. [112] Soundravally, R., Hoti, S.L., Patil, S.A., Cleetus, C.C., Zachariah, B., Kadhiravan, T., et al., Association between proinflammatory cytokines and lipid peroxidation in patients with severe dengue disease around defervescence. Int. J. Infect. Dis. 18 (2014), 68–72, 10.1016/j.ijid.2013.09.022.
113. [113] Escalera-Cueto, M., Medina-Martínez, I., del Angel, R.M., Berumen-Campos, J., Gutiérrez-Escolano, A.L., Yocupicio-Monroy, M., Let-7c overexpression inhibits dengue virus replication in human hepatoma Huh-7 cells. Virus Res. 196 (2015), 105–112, 10.1016/j.virusres.2014.11.010.
114. [114] Bressanelli, S., Stiasny, K., Allison, S.L., Stura, E.A., Duquerroy, S., Lescar, J., et al., Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J. 23 (2004), 728–738, 10.1038/sj.emboj.7600064.
115. [115] Modis, Y., Ogata, S., Clements, D., Harrison, S.C., Structure of the dengue virus envelope protein after membrane fusion. Nature 427 (2004), 313–319, 10.1038/nature02165.
116. [116] Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., et al., Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441 (2006), 101–105, 10.1038/nature04734.
117. [117] Nasirudeen, A.M.A., Wong, H.H., Thien, P., Xu, S., Lam, K.-P., Liu, D.X., RIG-I, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection. PLoS Negl. Trop. Dis., 5, 2011, e926, 10.1371/journal.pntd.0000926.
118. [118] Sariol, C.A., Martínez, M.I., Rivera, F., Rodríguez, I.V., Pantoja, P., Abel, K., et al., Decreased dengue replication and an increased anti-viral humoral response with the use of combined toll-like receptor 3 and 7/8 agonists in macaques. PLoS One, 6, 2011, e19323, 10.1371/journal.pone.0019323.
119. [119] Schoggins, J.W., MacDuff, D.A., Imanaka, N., Gainey, M.D., Shrestha, B., Eitson, J.L., et al., Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 505 (2014), 691–695, 10.1038/nature12862.
120. [120] Belgnaoui, S.M., Paz, S., Hiscott, J., Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter. Curr. Opin. Immunol. 23 (2011), 564–572, 10.1016/j.coi.2011.08.001.
121. [121] Hiscott, J., Convergence of the NF-kappaB and IRF pathways in the regulation of the innate antiviral response. Cytokine Growth Factor Rev. 18 (2007), 483–490, 10.1016/j.cytogfr.2007.06.002.
122. [122] Kawai, T., Akira, S., The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat. Immunol. 11 (2010), 373–384, 10.1038/ni.1863.
123. [123] Loo, Y.M., Gale, M. Jr., Immune signaling by RIG-I-like receptors. Immunity 34 (2011), 680–692, 10.1016/j.immuni.2011.05.003.
124. [124] Stark, G.R., Darnell, J.E., The JAK–STAT pathway at twenty. Immunity 36 (2012), 503–514, 10.1016/j.immuni.2012.03.013.
125. [125] Belgnaoui, S.M., Paz, S., Samuel, S., Goulet, M.-L., Sun, Q., Kikkert, M., et al., Linear ubiquitination of NEMO negatively regulates the interferon antiviral response through disruption of the MAVS–TRAF3 complex. Cell Host Microbe 12 (2012), 211–222, 10.1016/j.chom.2012.06.009.
126. [126] Gloire, G., Legrand-Poels, S., Piette, J., NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol. 72 (2006), 1493–1505, 10.1016/j.bcp.2006.04.011.
127. [127] Morgan, M.J., Liu, Z., Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res. 21 (2011), 103–115, 10.1038/cr.2010.178.
128. [128] Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B.T., Tschopp, J., Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320 (2008), 674–677, 10.1126/science.1156995.
129. [129] Jaiyen, Y., Masrinoul, P., Kalayanarooj, S., Pulmanausahakul, R., Ubol, S., Characteristics of dengue virus-infected peripheral blood mononuclear cell death that correlates with the severity of illness. Microbiol. Immunol. 53 (2009), 442–450, 10.1111/j.1348-0421.2009.00148.x.
130. [130] Hottz, E.D., Lopes, J.F., Freitas, C., Valls-de-Souza, R., Oliveira, M.F., Bozza, M.T., et al., Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation. Blood 122 (2013), 3405–3414, 10.1182/blood-2013-05-504449.
131. [131] Wu, M.-F., Chen, S.-T., Hsieh, S.-L., Distinct regulation of dengue virus-induced inflammasome activation in human macrophage subsets. J. Biomed. Sci., 20, 2013, 36, 10.1186/1423-0127-20-36.
132. [132] Hamel, R., Dejarnac, O., Wichit, S., Ekchariyawat, P., Neyret, A., Luplertlop, N., et al., Biology of Zika virus infection in human skin cells. J. Virol. 89 (2015), 8880–8896, 10.1128/JVI.00354-15.
133. [133] Kwissa, M., Nakaya, H.I., Onlamoon, N., Wrammert, J., Villinger, F., Perng, G.C., et al., Dengue virus infection induces expansion of a CD14(+)CD16(+) monocyte population that stimulates plasmablast differentiation. Cell Host Microbe 16 (2014), 115–127, 10.1016/j.chom.2014.06.001.
134. [134] Lazear, H.M., Pinto, A.K., Vogt, M.R., Gale, M., Diamond, M.S., Beta interferon controls West Nile virus infection and pathogenesis in mice. J. Virol. 85 (2011), 7186–7194, 10.1128/JVI.00396-11.
135. [135] Lee, N., Wong, C.K., Chan, P.K.S., Lun, S.W.M., Lui, G., Wong, B., et al., Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin. Infect. Dis. 45 (2007), 723–731, 10.1086/520981.
136. [136] Marovich, M., Grouard-Vogel, G., Louder, M., Eller, M., Sun, W., Wu, S.J., et al., Human dendritic cells as targets of dengue virus infection. J. Investig. Dermatol. Symp. Proc. 6 (2001), 219–224, 10.1046/j.0022-202x.2001.00037.x.
137. [137] Schmid, M.A., Diamond, M.S., Harris, E., Dendritic cells in dengue virus infection: targets of virus replication and mediators of immunity. Front. Immunol., 5, 2014, 647, 10.3389/fimmu.2014.00647.
138. [138] Tassaneetrithep, B., Burgess, T.H., Granelli-Piperno, A., Trumpfheller, C., Finke, J., Sun, W., et al., DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J. Exp. Med. 197 (2003), 823–829, 10.1084/jem.20021840.
139. [139] Gringhuis, S.I., van der Vlist, M., van den Berg, L.M., den Dunnen, J., Litjens, M., Geijtenbeek, T.B.H., HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat. Immunol. 11 (2010), 419–426, 10.1038/ni.1858.
140. [140] Engering, A., Geijtenbeek, T.B.H., van Vliet, S.J., Wijers, M., van Liempt, E., Demaurex, N., et al., The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J. Immunol. 168 (2002), 2118–2126.
141. [141] Meertens, L., Carnec, X., Lecoin, M.P., Ramdasi, R., Guivel-Benhassine, F., Lew, E., et al., The TIM and TAM families of phosphatidylserine receptors mediate dengue virus entry. Cell Host Microbe 12 (2012), 544–557, 10.1016/j.chom.2012.08.009.
142. [142] Perera-Lecoin, M., Meertens, L., Carnec, X., Amara, A., Flavivirus entry receptors: an update. Viruses 6 (2014), 69–88, 10.3390/v6010069.
143. [143] Palmer, D.R., Sun, P., Celluzzi, C., Bisbing, J., Pang, S., Sun, W., et al., Differential effects of dengue virus on infected and bystander dendritic cells. J. Virol. 79 (2005), 2432–2439, 10.1128/JVI.79.4.2432-2439.2005.
144. [144] Limon-Flores, A.Y., Perez-Tapia, M., Estrada-Garcia, I., Vaughan, G., Escobar-Gutierrez, A., Calderon-Amador, J., et al., Dengue virus inoculation to human skin explants: an effective approach to assess in situ the early infection and the effects on cutaneous dendritic cells. Int. J. Exp. Pathol. 86 (2005), 323–334, 10.1111/j.0959-9673.2005.00445.x.
145. [145] Rodriguez-Madoz, J.R., Belicha-Villanueva, A., Bernal-Rubio, D., Ashour, J., Ayllon, J., Fernandez-Sesma, A., Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex. J. Virol. 84 (2010), 9760–9774, 10.1128/JVI.01051-10.
146. [146] Rodriguez-Madoz, J.R., Bernal-Rubio, D., Kaminski, D., Boyd, K., Fernandez-Sesma, A., Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J. Virol. 84 (2010), 4845–4850, 10.1128/JVI.02514-09.
147. [147] Yu, C.-Y., Chang, T.-H., Liang, J.-J., Chiang, R.-L., Lee, Y.-L., Liao, C.-L., et al., Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog., 8, 2012, e1002780, 10.1371/journal.ppat.1002780.
148. [148] Dalrymple, N.A., Cimica, V., Mackow, E.R., Dengue virus NS proteins inhibit RIG-I/MAVS signaling by blocking TBK1/IRF3 phosphorylation: dengue virus serotype 1 NS4A is a unique interferon-regulating virulence determinant. MBio, 6, 2015, e00553-15, 10.1128/mBio.00553–15.
149. [149] Ho, L.-J., Hung, L.-F., Weng, C.-Y., Wu, W.-L., Chou, P., Lin, Y.-L., et al., Dengue virus type 2 antagonizes IFN-alpha but not IFN-gamma antiviral effect via down-regulating Tyk2-STAT signaling in the human dendritic cell. J. Immunol. 174 (2005), 8163–8172.
150. [150] Ashour, J., Laurent-Rolle, M., Shi, P.-Y., García-Sastre, A., NS5 of dengue virus mediates STAT2 binding and degradation. J. Virol. 83 (2009), 5408–5418, 10.1128/JVI.02188-08.
151. [151] Mazzon, M., Jones, M., Davidson, A., Chain, B., Jacobs, M., Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. J. Infect. Dis. 200 (2009), 1261–1270, 10.1086/605847.
152. [152] Muñoz-Jordán, J.L., Laurent-Rolle, M., Ashour, J., Martínez-Sobrido, L., Ashok, M., Lipkin, W.I., et al., Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 79 (2005), 8004–8013, 10.1128/JVI.79.13.8004-8013.2005.
153. [153] Jheng, J.-R., Ho, J.-Y., Horng, J.-T., ER stress, autophagy, and RNA viruses. Front. Microbiol., 5, 2014, 388, 10.3389/fmicb.2014.00388.
154. [154] Blázquez, A.-B., Escribano-Romero, E., Merino-Ramos, T., Saiz, J.-C., Martín-Acebes, M.A., Stress responses in flavivirus-infected cells: activation of unfolded protein response and autophagy. Front. Microbiol., 5, 2014, 266, 10.3389/fmicb.2014.00266.
155. [155] Richards, A.L., Jackson, W.T., How positive-strand RNA viruses benefit from autophagosome maturation. J. Virol. 87 (2013), 9966–9972, 10.1128/JVI.00460-13.
156. [156] Lee, Y.-R., Lei, H.-Y., Liu, M.-T., Wang, J.-R., Chen, S.-H., Jiang-Shieh, Y.-F., et al., Autophagic machinery activated by dengue virus enhances virus replication. Virology 374 (2008), 240–248, 10.1016/j.virol.2008.02.016.
157. [157] Khakpoor, A., Panyasrivanit, M., Wikan, N., Smith, D.R., A role for autophagolysosomes in dengue virus 3 production in HepG2 cells. J. Gen. Virol. 90 (2009), 1093–1103, 10.1099/vir.0.007914-0.
158. [158] Panyasrivanit, M., Khakpoor, A., Wikan, N., Smith, D.R., Co-localization of constituents of the dengue virus translation and replication machinery with amphisomes. J. Gen. Virol. 90 (2009), 448–456, 10.1099/vir.0.005355-0.
159. [159] Mateo, R., Nagamine, C.M., Spagnolo, J., Méndez, E., Rahe, M., Gale, M., et al., Inhibition of cellular autophagy deranges dengue virion maturation. J. Virol. 87 (2013), 1312–1321, 10.1128/JVI.02177-12.
160. [160] Heaton, N.S., Randall, G., Dengue virus-induced autophagy regulates lipid metabolism. Cell Host Microbe 8 (2010), 422–432, 10.1016/j.chom.2010.10.006.
161. [161] Fang, Y.-T., Wan, S.-W., Lu, Y.-T., Yao, J.-H., Lin, C.-F., Hsu, L.-J., et al., Autophagy facilitates antibody-enhanced dengue virus infection in human pre-basophil/mast cells. PLoS One, 9, 2014, e110655, 10.1371/journal.pone.0110655.
162. [162] Jounai, N., Takeshita, F., Kobiyama, K., Sawano, A., Miyawaki, A., Xin, K.-Q., et al., The Atg5 Atg12 conjugate associates with innate antiviral immune responses. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 14050–14055, 10.1073/pnas.0704014104.
163. [163] Ubol, S., Phuklia, W., Kalayanarooj, S., Modhiran, N., Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J. Infect. Dis. 201 (2010), 923–935, 10.1086/651018.
164. [164] Zellweger, R.M., Shresta, S., Mouse models to study dengue virus immunology and pathogenesis. Front. Immunol., 5, 2014, 151, 10.3389/fimmu.2014.00151.
165. [165] Zompi, S., Harris, E., Animal models of dengue virus infection. Viruses 4 (2012), 62–82, 10.3390/v4010062.
166. [166] Aguirre, S., Maestre, A.M., Pagni, S., Patel, J.R., Savage, T., Gutman, D., et al., DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog., 8, 2012, e1002934, 10.1371/journal.ppat.1002934.
167. [167] Züst, R., Toh, Y.-X., Valdés, I., Cerny, D., Heinrich, J., Hermida, L., et al., Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines. J. Virol. 88 (2014), 7276–7285, 10.1128/JVI.03827–13.
168. [168] Durbin, A.P., Vargas, M.J., Wanionek, K., Hammond, S.N., Gordon, A., Rocha, C., et al., Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology 376 (2008), 429–435, 10.1016/j.virol.2008.03.028.
169. [169] Pinto, A.K., Brien, J.D., Lam, C.-Y.K., Johnson, S., Chiang, C., Hiscott, J., et al., Defining new therapeutics using a more immunocompetent mouse model of antibody-enhanced dengue virus infection. MBio, 6, 2015, e01316-15, 10.1128/mBio.01316–15.
170. [170] Brien, J.D., Sukupolvi-Petty, S., Williams, K.L., Lam, C.-Y.K., Schmid, M.A., Johnson, S., et al., Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus. J. Virol. 87 (2013), 7747–7753, 10.1128/JVI.00327-13.
171. [171] Goulet, M.L., Olagnier, D., Xu, Z., Paz, S., Belgnaoui, S.M., Lafferty, E.I., et al., Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PLoS Pathog., 9, 2013, e1003298, 10.1371/journal.ppat.1003298.
172. [172] Chiang, C., Beljanski, V., Yin, K., Olagnier, D., Ben Yebdri, F., Steel, C., et al., Sequence-specific modifications enhance the broad-spectrum antiviral response activated by RIG-I agonists. J. Virol.(89), 2015, 8011–8025, 10.1128/JVI.00845–15.
173. [173] Beljanski, V., Chiang, C., Kirchenbaum, G.A., Olagnier, D., Bloom, C.E., Wong, T., et al., Enhanced influenza virus-like particle vaccination with a structurally optimized RIG-I agonist as adjuvant. J. Virol. 89 (2015), 10612–10624, 10.1128/JVI.01526–15.
174. [174] Becker, R., Missing link: Animal models to study whether Zika causes birth defects. Nat. Med. 22 (2016), 225–227, 10.1038/nm0316-225.
175. [175] Rossi, S.L., Tesh, R.B., Azar, S.R., Muruato, A.E., Hanley, K.A., Auguste, A.J., et al. Characterization of a novel murine model to study Zika virus. Am. J. Trop. Med. Hyg., 2016, 10.4269/ajtmh.16-0111.
176. [176] Lazear, H.M., Govero, J., Smith, A.M., Platt, D.J., Fernandez, E., Miner, J.J., Diamond, M.S., A mouse model of Zika virus pathogenesis. Cell Host Microbe, 2016, 10.1016/j.chom.2016.03.010.
177. [177] Aliota, M.T., Caine, E.A., Walker, E.C., Larkin, K.E., Camacho, E., Osorio, J.E., Characterization of lethal zika Virus Infection in AG129 Mice. PLoS Negl Trop Dis., 10(4), 2016, e0004682, 10.1371/journal.pntd.0004682.
178. [178] Mufson, S., $1.8 billion to fight Zika: CDC moves to highest alert level. (n.d.) https://www.washingtonpost.com/news/post-politics/wp/2016/02/08/obama-to-ask-congress-for-1-8-billion-to-combat-zika-virus/.
179. [179] Capeding, M.R., Tran, N.H., Hadinegoro, S.R.S., Ismail, H.I.H.M., Chotpitayasunondh, T., Chua, M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384 (2014), 1358–1365, 10.1016/S0140-6736(14)61060-6.
180. [180] Osorio, J.E., Velez, I.D., Thomson, C., Lopez, L., Jimenez, A., Haller, A.A., et al. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect. Dis. 14 (2014), 830–838, 10.1016/S1473-3099(14)70811-4.
181. [181] Villar, L., Dayan, G.H., Arredondo-García, J.L., Rivera, D.M., Cunha, R., Deseda, C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N. Engl. J. Med. 372 (2015), 113–123, 10.1056/NEJMoa1411037.
182. [182] Kirkpatrick, B.D., Durbin, A.P., Pierce, K.K., Carmolli, M.P., Tibery, C.M., Grier, P.L., et al. Robust and balanced immune responses to all 4 dengue virus serotypes following administration of a single dose of a live attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults. J. Infect. Dis. 212 (2015), 702–710, 10.1093/infdis/jiv082.